FDA grants priority review to olaparib/abiraterone combo for mCRPCAugust 16th 2022
The application is supported by the phase 3 PROpel trial, which showed that adding olaparib to frontline abiraterone acetate and prednisone/prednisolone significantly improved radiographic progression-free survival in patients with mCRPC.
Reader reproducibility high with 18F-rhPSMA-7.3 image interpretation in prostate cancerJune 15th 2022
“These findings from the SPOTLIGHT study showed high inter-reader and intra-reader agreement for interpretation of 18F-rhPSMA-7.3 PET/CT scans in the setting of biochemical recurrence,” said Phillip Kuo, MD, PhD.
PSA response linked to improved survival with darolutamide triplet in mHSPCJune 8th 2022
Overall survival was higher among patients with mHSPC who achieved undetectable PSA levels when treated with the triplet of darolutamide, ADT, and docetaxel, according to an analysis from the phase 3 ARASENS trial.
PSMA-PET criteria identified to optimize mCRPC patient selection for 177Lu-PSMA-617June 5th 2022
"PSMA-PET imaging reports on individual lesions of patients with mCRPC could include SUVmean prior to starting 177Lu-PSMA-617 therapy to provide important prognostic information on potential treatment responses and long-term outcomes," said Andrew J. Armstrong, MD.
Toripalimab active in urothelial carcinoma, predictive biomarkers emergeJune 4th 2022
The PD-1 inhibitor toripalimab is approved in China for the treatment of patients with locally advanced or metastatic urothelial carcinoma who failed platinum-containing chemotherapy or progressed within 12 months of receiving neoadjuvant or adjuvant platinum-containing chemotherapy.